vs
Amphastar Pharmaceuticals, Inc.（AMPH）与Applied Digital Corp.（APLD）财务数据对比。点击上方公司名可切换其他公司
Amphastar Pharmaceuticals, Inc.的季度营收约是Applied Digital Corp.的1.4倍（$183.1M vs $126.6M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs -11.4%，领先24.8%），Applied Digital Corp.同比增速更快（98.2% vs -1.8%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $-567.9M），过去两年Applied Digital Corp.的营收复合增速更高（70.9% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
BAE系统旗下的国际防务与安全技术企业，专注于提供数字化解决方案，支持客户快速开展数据驱动决策，服务覆盖执法机构、国家安全部门、政府单位、关键基础设施运营商、电信企业、军方及航天领域。
AMPH vs APLD — 直观对比
营收规模更大
AMPH
是对方的1.4倍
$126.6M
营收增速更快
APLD
高出100.0%
-1.8%
净利率更高
AMPH
高出24.8%
-11.4%
自由现金流更多
AMPH
多$592.5M
$-567.9M
两年增速更快
APLD
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $126.6M |
| 净利润 | $24.4M | $-14.4M |
| 毛利率 | 46.8% | 20.6% |
| 营业利润率 | 19.4% | -24.5% |
| 净利率 | 13.3% | -11.4% |
| 营收同比 | -1.8% | 98.2% |
| 净利润同比 | -35.7% | 89.6% |
| 每股收益（稀释后） | $0.51 | $-0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHAPLD
| Q4 25 | $183.1M | $126.6M | ||
| Q3 25 | $191.8M | $64.2M | ||
| Q2 25 | $174.4M | $-33.3M | ||
| Q1 25 | $170.5M | $52.9M | ||
| Q4 24 | $186.5M | $63.9M | ||
| Q3 24 | $191.2M | $60.7M | ||
| Q2 24 | $182.4M | $43.7M | ||
| Q1 24 | $171.8M | $43.3M |
净利润AMPHAPLD
| Q4 25 | $24.4M | $-14.4M | ||
| Q3 25 | $17.4M | $-16.9M | ||
| Q2 25 | $31.0M | $-52.5M | ||
| Q1 25 | $25.3M | $-35.6M | ||
| Q4 24 | $38.0M | $-138.7M | ||
| Q3 24 | $40.4M | $-4.2M | ||
| Q2 24 | $37.9M | $-64.5M | ||
| Q1 24 | $43.2M | $-62.8M |
毛利率AMPHAPLD
| Q4 25 | 46.8% | 20.6% | ||
| Q3 25 | 51.4% | 13.4% | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | 7.1% | ||
| Q4 24 | 46.5% | 18.0% | ||
| Q3 24 | 53.3% | -0.6% | ||
| Q2 24 | 52.2% | -9.1% | ||
| Q1 24 | 52.4% | -8.6% |
营业利润率AMPHAPLD
| Q4 25 | 19.4% | -24.5% | ||
| Q3 25 | 13.2% | -34.7% | ||
| Q2 25 | 24.2% | — | ||
| Q1 25 | 21.9% | -35.8% | ||
| Q4 24 | 24.2% | -29.1% | ||
| Q3 24 | 29.8% | 15.6% | ||
| Q2 24 | 30.3% | -68.4% | ||
| Q1 24 | 27.9% | -128.8% |
净利率AMPHAPLD
| Q4 25 | 13.3% | -11.4% | ||
| Q3 25 | 9.0% | -26.4% | ||
| Q2 25 | 17.8% | 157.8% | ||
| Q1 25 | 14.8% | -67.2% | ||
| Q4 24 | 20.4% | -217.2% | ||
| Q3 24 | 21.1% | -7.0% | ||
| Q2 24 | 20.8% | -147.5% | ||
| Q1 24 | 25.1% | -145.0% |
每股收益（稀释后）AMPHAPLD
| Q4 25 | $0.51 | $-0.07 | ||
| Q3 25 | $0.37 | $-0.07 | ||
| Q2 25 | $0.64 | $-0.31 | ||
| Q1 25 | $0.51 | $-0.16 | ||
| Q4 24 | $0.74 | $-0.66 | ||
| Q3 24 | $0.78 | $-0.03 | ||
| Q2 24 | $0.73 | $-0.57 | ||
| Q1 24 | $0.81 | $-0.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $1.9B |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $1.4B |
| 总资产 | $1.6B | $5.2B |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHAPLD
| Q4 25 | $282.8M | $1.9B | ||
| Q3 25 | $276.2M | $73.9M | ||
| Q2 25 | $231.8M | $41.6M | ||
| Q1 25 | $236.9M | $68.7M | ||
| Q4 24 | $221.6M | $286.2M | ||
| Q3 24 | $250.5M | $58.2M | ||
| Q2 24 | $217.8M | $3.3M | ||
| Q1 24 | $289.6M | $4.4M |
总债务AMPHAPLD
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHAPLD
| Q4 25 | $788.8M | $1.4B | ||
| Q3 25 | $776.7M | $1.0B | ||
| Q2 25 | $757.5M | $497.7M | ||
| Q1 25 | $751.3M | $454.6M | ||
| Q4 24 | $732.3M | $434.6M | ||
| Q3 24 | $727.7M | $241.8M | ||
| Q2 24 | $713.3M | $124.8M | ||
| Q1 24 | $672.4M | $118.5M |
总资产AMPHAPLD
| Q4 25 | $1.6B | $5.2B | ||
| Q3 25 | $1.7B | $2.4B | ||
| Q2 25 | $1.6B | $1.9B | ||
| Q1 25 | $1.6B | $1.7B | ||
| Q4 24 | $1.6B | $1.5B | ||
| Q3 24 | $1.5B | $937.7M | ||
| Q2 24 | $1.5B | $762.9M | ||
| Q1 24 | $1.6B | $643.2M |
负债/权益比AMPHAPLD
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $-15.8M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $-567.9M |
| 自由现金流率自由现金流/营收 | 13.4% | -448.6% |
| 资本支出强度资本支出/营收 | 4.5% | 436.1% |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | $-1.3B |
8季度趋势，按日历期对齐
经营现金流AMPHAPLD
| Q4 25 | $32.9M | $-15.8M | ||
| Q3 25 | $52.6M | $-82.0M | ||
| Q2 25 | $35.6M | $6.9M | ||
| Q1 25 | $35.1M | $5.9M | ||
| Q4 24 | $29.0M | $-52.3M | ||
| Q3 24 | $60.0M | $-75.9M | ||
| Q2 24 | $69.1M | $-34.1M | ||
| Q1 24 | $55.3M | $38.8M |
自由现金流AMPHAPLD
| Q4 25 | $24.6M | $-567.9M | ||
| Q3 25 | $47.2M | $-331.4M | ||
| Q2 25 | $25.0M | $-191.4M | ||
| Q1 25 | $24.4M | $-251.6M | ||
| Q4 24 | $16.6M | $-223.3M | ||
| Q3 24 | $46.2M | $-130.7M | ||
| Q2 24 | $63.1M | $-88.9M | ||
| Q1 24 | $46.5M | $-2.3M |
自由现金流率AMPHAPLD
| Q4 25 | 13.4% | -448.6% | ||
| Q3 25 | 24.6% | -516.1% | ||
| Q2 25 | 14.3% | 574.8% | ||
| Q1 25 | 14.3% | -475.4% | ||
| Q4 24 | 8.9% | -349.6% | ||
| Q3 24 | 24.1% | -215.3% | ||
| Q2 24 | 34.6% | -203.5% | ||
| Q1 24 | 27.1% | -5.4% |
资本支出强度AMPHAPLD
| Q4 25 | 4.5% | 436.1% | ||
| Q3 25 | 2.8% | 388.4% | ||
| Q2 25 | 6.1% | -595.4% | ||
| Q1 25 | 6.3% | 486.6% | ||
| Q4 24 | 6.7% | 267.8% | ||
| Q3 24 | 7.2% | 90.3% | ||
| Q2 24 | 3.3% | 125.4% | ||
| Q1 24 | 5.1% | 95.0% |
现金转化率AMPHAPLD
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
APLD
| HPC Hosting Business | $85.0M | 67% |
| Data Center Hosting Business | $41.6M | 33% |
